Date(s) - 03/10/2019
5:00 pm - 6:00 pm
Comprehensive LC-MS-based characterization of therapeutic proteins requires detailed molecular knowledge of every residue and side chain, as well as every intact protein isoform.
With the goal of maximizing molecular understanding per unit time we will discuss a platform for addressing the versatility and throughput requirements of performing comprehensive characterization. We will focus on applying advanced versions of multiple key characterization workflows using a battery of state-of-the-art LC-MS methods performed on a single Orbitrap™ mass spectrometer.
Key Learning Objectives:
- How to go beyond and push your current biopharma characterization limitations
- Address advanced biotherapeutic drug heterogeneity
- Learn more about your molecule and gain confidence in its safety and efficacy
Who Should Attend:
Researchers, Lab Technicians, Directors, and service providers or CROs in biopharma interested in:
- In-depth characterization of advance biotherapeutics
- Native intact mass analysis, including native top-down approaches
- Top & middle down protein characterization with multiple fragmentation approaches
For questions please contact Kristen Moore: firstname.lastname@example.org
Aaron O. Bailey, PhD
Associate Director, MS Products
Dr. Aaron Bailey is currently the Product Manager of Mass Spectrometry Services at BGI Americas. He began training in mass spectrometry as a technician in the laboratory of Prof. John R. Yates III at The Scripps Research Institute using MuDPIT technology for a variety of cell biology research projects. Dr. Bailey earned his Ph.D. in Cell Biology at the University of Virginia, with the joint mentorship of Prof. Donald F. Hunt and Prof. Daniel R. Foltz, using both classical biochemistry techniques and high-resolution middle-down LC/MS peptide mapping to characterize human centromeric histones variants. Dr. Bailey joined Thermo Fisher Scientific in 2013, where he developed and managed new intact protein characterization workflows, specifically focusing on key technologies for coupling online separations to native MS applications. Currently, Dr. Bailey is responsible for the management and development of the Mass Spectrometry Services portfolio at the newly built MS Service Lab in San Jose, California, to support high throughput proteomic and biologics characterization services, and continuing to focus on developing new technologies for intact mass measurements of “out-of-reach” complex biologic drugs.